1
Clinical Trials associated with P10s-PADRE/ MONTANIDE ISA 51 VG(University of Arkansas)A Combined Phase i/II Efficacy Study of a Carbohydrate Mimotope-based Vaccine With MONTANIDE™ ISA 51 VG STERILE Combined With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III triple negative breast cancer (TNBC). This study will compare the vaccine plus standard neoadjuvant chemotherapy and surgery to standard neoadjuvant chemotherapy and surgery alone.
100 Clinical Results associated with P10s-PADRE/ MONTANIDE ISA 51 VG(University of Arkansas)
100 Translational Medicine associated with P10s-PADRE/ MONTANIDE ISA 51 VG(University of Arkansas)
100 Patents (Medical) associated with P10s-PADRE/ MONTANIDE ISA 51 VG(University of Arkansas)
100 Deals associated with P10s-PADRE/ MONTANIDE ISA 51 VG(University of Arkansas)